Who is sponsoring NCT04696666?

NCT04696666 is sponsored by LIDDE Therapeutics.

What drugs are being tested in NCT04696666?

Interventions in NCT04696666: INSTYLAN (Sodium Hyaluronate 80mg/50ml).

What condition does NCT04696666 study?

NCT04696666 studies Hemorrhagic Cystitis.

Is NCT04696666 still recruiting?

NCT04696666 is currently status unknown. Last updated 6 January 2021.

Last reviewed 2021-01-06 · How we verify

NCT04696666

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tolerability and Efficacy of INSTYLAN in Subjects With Moderate to Severe Hemorrhagic Cystitis

Status unknown NA Last updated 6 January 2021

What this trial tests

NA trial testing INSTYLAN (Sodium Hyaluronate 80mg/50ml) in Hemorrhagic Cystitis in 30 participants. Status unknown.

Timeline

15 May 2020

Primary endpoint
30 May 2021

30 July 2021

Quick facts

Lead sponsor	LIDDE Therapeutics
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	15 May 2020
Primary completion	30 May 2021
Estimated completion	30 July 2021
Sites	10 locations across France

Drugs / interventions tested

INSTYLAN (Sodium Hyaluronate 80mg/50ml)

Conditions studied

Hemorrhagic Cystitis — all drugs for Hemorrhagic Cystitis →

Sponsor

LIDDE Therapeutics

Who can join

Adults 18 to 80, any sex, with Hemorrhagic Cystitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the efficacy and tolerability of INSTYLAN (Sodium Hyaluronate 80mg/50ml) in Patients with early or late symptoms of moderate to severe hemorrhagic cystitis caused by pelvic radiation therapy and/or chemotherapy. The study is conducted in the field of routine clinical practice and will recruit 30 subjects treated with intravesical instillations with INSTYLAN weekly for 6 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hemorrhagic Cystitis

Currently open trials in the same condition.

NCT06241274 — Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCT · NA · recruiting
NCT06198517 — Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04696666 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LIDDE Therapeutics
Last refreshed: 6 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04696666.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing